Combination treatment for amyotrophic lateral sclerosis (ALS)

Patent metadata

Field	Value
Publication number	US-10220077-B2
Application number	US-201314442731-A
Country	US
Kind code	B2
Filing date	Nov 14, 2013
Priority date	Nov 14, 2012
Publication date	Mar 5, 2019
Grant date	Mar 5, 2019

Abstract

A method of treating a disease selected from the group consisting of emphysema, sepsis, septic shock, ischemic injury, cerebral ischemia, a neurodegenerative disorder, meningitis, encephalitis, hemorrhage, cerebral ischemia, heart ischemia and a cognitive deficit in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a combination of at least two agents, wherein a first of said two agents upregulates an activity and/or expression of Nrf2 and a second of said two agents is a glutamatergic modulator, thereby treating the disease.

First claim

What is claimed is:

1. A method of treating a disease selected from the group consisting of ischemic injury, cerebral ischemia, and a neurodegenerative disorder selected from the group consisting of amyotrophic lateral sclerosis, and multiple system atrophy, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a combination of three agents, wherein a first of said three agents is a polynucleotide encoding Nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a second of said three agents is a polynucleotide encoding a glutamate transporter and a third of said three agents is a polynucleotide encoding a glutamate dehydrogenase, thereby treating the disease, and wherein the glutamate transporter is excitatory amino acid transporter (EAAT) 2 (EAAT2) and the glutamate dehydrogenase is glutamate dehydrogenase 2 (GDH2).

2. The method of claim 1 , wherein the neurodegenerative disorder is amyotrophic lateral sclerosis or multiple system atrophy.

3. The method of claim 1 , further comprising administering an antioxidant.

4. The method of claim 3 , wherein said antioxidant comprises an agent selected from the group consisting of Coenzyme Q10, thiol, ascorbic acid, polyphenol, glutathione, vitamin C, vitamin E, catalase, superoxide dismutase and peroxidase.

5. The method of claim 1 , wherein said administering is effected via intra-cisternal (I.C.) administration or intra-muscular (I.M.) administration.

6. The method of claim 1 , wherein said disease is ischemic injury or cerebral ischemia.

Assignees

• Offen Daniel
• Univ Ramot

Inventors

• Benkler Chen
• Offen Daniel

Classifications

• C12N2740/15043

  viral genome or elements thereof as genetic vector · CPC title

• A61K48/005

  characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered · CPC title

• A61K38/43

  Enzymes; Proenzymes; Derivatives thereof · CPC title

• A01K2267/0318

  Animal model for neurodegenerative disease, e.g. non- Alzheimer's · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title